Famciclovir
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Famciclovir: From Herpes Zoster to Post-infectious Neuralgia
One-Sentence Summary
Famciclovir is an oral antiviral originally used to treat herpes zoster (shingles). The TxGNN model predicts it may be useful for post-infectious neuralgia, which in this context is nerve pain after a viral infection such as postherpetic neuralgia. Support is thin: 1 clinical trial is linked, and it tests a different drug (oxycodone), with no publications found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Herpes zoster |
| Predicted New Indication | Post-infectious neuralgia |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known pharmacology, famciclovir is a prodrug of penciclovir. Penciclovir’s active triphosphate form inhibits the DNA polymerase of varicella-zoster virus (VZV), which limits viral replication.
The link between the two conditions is that postherpetic neuralgia is the most common complication of herpes zoster. Treating the acute zoster episode early with an antiviral may reduce nerve damage and, in turn, the risk or duration of later neuralgia. The reasoning is plausible but indirect. The only linked trial studies oxycodone, not famciclovir, so there is no direct evidence that famciclovir prevents or treats post-infectious neuralgia.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03120962 | Not applicable | Unknown | 140 | Tests early oxycodone during acute herpes zoster to prevent postherpetic neuralgia. Famciclovir is not the studied drug, so this offers contextual support only. |
Literature Evidence
Currently no related literature available.
Canada Market Information
Six valid single-ingredient authorizations are on the Canadian market. Dosage forms, manufacturers and approved-indication text are not available in the data compiled for this report.
| DIN | Product Name |
|---|---|
| 02292041 | APO-FAMCICLOVIR |
| 02292068 | APO-FAMCICLOVIR |
| 02177102 | FAMVIR |
| 02229129 | FAMVIR |
| 02229110 | FAMVIR |
(5 of 6 authorizations shown; the sixth is another APO-FAMCICLOVIR product, DIN 02292025.)
Safety Considerations
- Disease-level contraindications (from a knowledge graph, not label text): kidney disease and pyoureter. This is relevant because famciclovir is cleared by the kidneys. Confirm against the Canadian product monograph before any use.
- Drug Interactions: 84 potential interactions were identified, none with a severity level assigned. Examples include calcitriol, doxycycline, metformin, glimepiride, morphine, omeprazole, pantoprazole, prednisone, simvastatin and vancomycin. Clinical significance needs verification.
Please refer to the package insert for label warnings and formal contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, and the mechanism is plausible because famciclovir treats the infection that precedes postherpetic neuralgia. However, no trial or publication tests famciclovir for this outcome, so the evidence is at the L4 level. The prediction should stay a research question for now.
To proceed, the following is needed:
- A trial or systematic review of famciclovir or other antivirals for preventing or treating postherpetic neuralgia
- Mechanism-of-action data from a curated source
- Label warnings and contraindications from the Canadian product monograph
- Dose guidance for patients with renal impairment
- Approved-indication text for the Canadian authorizations
Related finding: Among the other predictions for famciclovir, chickenpox has the strongest support (L1). It has two completed Phase 3 studies, one on pediatric pharmacokinetics and safety (NCT00098046) and one on zoster efficacy (NCT01327144). Neither is a chickenpox efficacy trial, so this is worth a separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.